Charles Duncan
Stock Analyst at Cantor Fitzgerald
(4.30)
# 410
Out of 4,983 analysts
226
Total ratings
44.76%
Success rate
20.12%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $5.10 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $23.96 | +16.86% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $126.54 | +18.54% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $114.10 | +34.09% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $12.63 | +10.85% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $45.43 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $13.49 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $23.16 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $32.29 | +79.62% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $27.39 | +56.99% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $49.76 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.17 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $140.90 | +10.01% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.50 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $13.26 | +163.95% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.46 | +191.48% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.04 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.61 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.71 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.65 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $20.07 | +69.41% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $34.10 | +46.63% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $5.41 | -7.58% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.38 | +947.12% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.07 | +273.83% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $35.69 | +62.51% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.84 | +59,845.50% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $6.33 | +1,163.82% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.08 | +177.78% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $8.96 | +22.77% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $8.85 | +35.59% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $8.56 | +1,862.62% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.29 | +773.36% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $21.18 | +844.51% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.14 | +250.88% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $2.09 | +1,048.33% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $2.28 | +6,215.79% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.25 | +220.00% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $75.85 | -48.58% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $71.32 | -78.97% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.51 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $3.63 | +4,858.68% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.10
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $23.96
Upside: +16.86%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $126.54
Upside: +18.54%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $114.10
Upside: +34.09%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $12.63
Upside: +10.85%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $45.43
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.49
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $23.16
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $32.29
Upside: +79.62%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $27.39
Upside: +56.99%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $49.76
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.17
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $140.90
Upside: +10.01%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.50
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $13.26
Upside: +163.95%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.46
Upside: +191.48%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.04
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.61
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.71
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.65
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $20.07
Upside: +69.41%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $34.10
Upside: +46.63%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $5.41
Upside: -7.58%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.38
Upside: +947.12%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.07
Upside: +273.83%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $35.69
Upside: +62.51%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.84
Upside: +59,845.50%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $6.33
Upside: +1,163.82%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.08
Upside: +177.78%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $8.96
Upside: +22.77%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $8.85
Upside: +35.59%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $8.56
Upside: +1,862.62%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.29
Upside: +773.36%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $21.18
Upside: +844.51%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.14
Upside: +250.88%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $2.09
Upside: +1,048.33%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $2.28
Upside: +6,215.79%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.25
Upside: +220.00%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $75.85
Upside: -48.58%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $71.32
Upside: -78.97%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.51
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $3.63
Upside: +4,858.68%